Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ

Michaela R Reagan, F Philipp Seib, Douglas W McMillin, Elizabeth K Sage, Constantine S Mitsiades, Sam M Janes, Irene M Ghobrial, David L Kaplan

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, at effective doses remains challenging. Herein we demonstrate the utility of a scaffold-based delivery system for sustained therapeutic cell release that capitalizes on the tumor-homing properties of mesenchymal stem cells (MSCs) and their ability to express genetically-introduced therapeutic genes.
LanguageEnglish
Pages273-282
Number of pages10
JournalJournal of breast cancer
Volume15
Issue number3
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Neoplastic Stem Cells
Mesenchymal Stromal Cells
Apoptosis
Neoplasms
Tumor Necrosis Factor-alpha
Ligands
Peptides
Therapeutics
Genes

Keywords

  • breast neoplasms
  • mesenchymal stem cells
  • tissue engineering
  • tissue therapy
  • TNF-related apoptosis-inducing ligand

Cite this

Reagan, M. R., Seib, F. P., McMillin, D. W., Sage, E. K., Mitsiades, C. S., Janes, S. M., ... Kaplan, D. L. (2012). Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. Journal of breast cancer, 15(3), 273-282. https://doi.org/10.4048/jbc.2012.15.3.273
Reagan, Michaela R ; Seib, F Philipp ; McMillin, Douglas W ; Sage, Elizabeth K ; Mitsiades, Constantine S ; Janes, Sam M ; Ghobrial, Irene M ; Kaplan, David L. / Stem cell implants for cancer therapy : TRAIL-expressing mesenchymal stem cells target cancer cells in situ. In: Journal of breast cancer. 2012 ; Vol. 15, No. 3. pp. 273-282.
@article{15051e261d9543e181bf8c71bf69b0be,
title = "Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ",
abstract = "Tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, at effective doses remains challenging. Herein we demonstrate the utility of a scaffold-based delivery system for sustained therapeutic cell release that capitalizes on the tumor-homing properties of mesenchymal stem cells (MSCs) and their ability to express genetically-introduced therapeutic genes.",
keywords = "breast neoplasms, mesenchymal stem cells, tissue engineering, tissue therapy, TNF-related apoptosis-inducing ligand",
author = "Reagan, {Michaela R} and Seib, {F Philipp} and McMillin, {Douglas W} and Sage, {Elizabeth K} and Mitsiades, {Constantine S} and Janes, {Sam M} and Ghobrial, {Irene M} and Kaplan, {David L}",
year = "2012",
month = "9",
doi = "10.4048/jbc.2012.15.3.273",
language = "English",
volume = "15",
pages = "273--282",
journal = "Journal of breast cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "3",

}

Reagan, MR, Seib, FP, McMillin, DW, Sage, EK, Mitsiades, CS, Janes, SM, Ghobrial, IM & Kaplan, DL 2012, 'Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ' Journal of breast cancer, vol. 15, no. 3, pp. 273-282. https://doi.org/10.4048/jbc.2012.15.3.273

Stem cell implants for cancer therapy : TRAIL-expressing mesenchymal stem cells target cancer cells in situ. / Reagan, Michaela R; Seib, F Philipp; McMillin, Douglas W; Sage, Elizabeth K; Mitsiades, Constantine S; Janes, Sam M; Ghobrial, Irene M; Kaplan, David L.

In: Journal of breast cancer, Vol. 15, No. 3, 09.2012, p. 273-282.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Stem cell implants for cancer therapy

T2 - Journal of breast cancer

AU - Reagan, Michaela R

AU - Seib, F Philipp

AU - McMillin, Douglas W

AU - Sage, Elizabeth K

AU - Mitsiades, Constantine S

AU - Janes, Sam M

AU - Ghobrial, Irene M

AU - Kaplan, David L

PY - 2012/9

Y1 - 2012/9

N2 - Tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, at effective doses remains challenging. Herein we demonstrate the utility of a scaffold-based delivery system for sustained therapeutic cell release that capitalizes on the tumor-homing properties of mesenchymal stem cells (MSCs) and their ability to express genetically-introduced therapeutic genes.

AB - Tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, at effective doses remains challenging. Herein we demonstrate the utility of a scaffold-based delivery system for sustained therapeutic cell release that capitalizes on the tumor-homing properties of mesenchymal stem cells (MSCs) and their ability to express genetically-introduced therapeutic genes.

KW - breast neoplasms

KW - mesenchymal stem cells

KW - tissue engineering

KW - tissue therapy

KW - TNF-related apoptosis-inducing ligand

U2 - 10.4048/jbc.2012.15.3.273

DO - 10.4048/jbc.2012.15.3.273

M3 - Article

VL - 15

SP - 273

EP - 282

JO - Journal of breast cancer

JF - Journal of breast cancer

SN - 1738-6756

IS - 3

ER -